A pulmonary assessment tool.
The Chartis System is a unique assessment tool that provides precise flow and pressure readings at the lobar or segmental level. This information enables the physician to make assessments regarding the level of collateral ventilation, or inter-lobar airflow in the lungs. Collateral ventilation (CV) can limit the effectiveness of endobronchial lung-volume reduction therapy, and is therefore an important predictor of EBV treatment success.1,2
By directly detecting the presence of CV in the targeted lobes of the lungs, this innovative technology platform empowers physicians to plan data-driven treatment with Zephyr valve therapy.
| How it works: | |
| The Chartis System includes a balloon catheter and a simple, easy-to-use console. The Chartis catheter is inserted via the working channel of the bronchoscope into the airway and the balloon is inflated. The balloon is designed to enable precise flow and pressure readings by the console. |
The balloon occludes the airway, blocking flow of inspired air from the lung compartment. The Chartis console displays expiratory air flow (orange), pressure (blue), and resistance (green) measurements. |
Footnotes
1. Gompelmann D, Eberhardt R, Ernst A, et al. Predicting Atelectasis Using Collateral Ventilation Assessment prior to Endobronchial Lung Volume Reduction – A Feasibility Study. Respiration 2010;80:419-425; doi: 10.1159/000319441.
2. Use of Chartis® Pulmonary Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR). Chartis Multi-Centre Study, data presented at ATS2011. Data on file with Pulmonx.
Zephyr® EBV is an Investigational Device in the United States. Limited by U.S. law to investigational use. Chartis® system is for use/sale outside the U.S. only.
